Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis.

[1]  Devjit Tripathy,et al.  Actos Now for the prevention of diabetes (ACT NOW) study , 2009, BMC endocrine disorders.

[2]  M. Quon,et al.  Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. , 2009, Atherosclerosis.

[3]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[4]  T. Trikalinos,et al.  Statins, low-density lipoprotein cholesterol, and risk of cancer. , 2008, Journal of the American College of Cardiology.

[5]  H. Milionis,et al.  Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. , 2008, European journal of pharmacology.

[6]  G. Watts,et al.  Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. , 2008, Atherosclerosis.

[7]  C. Michael White,et al.  The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials , 2008 .

[8]  G. Watts,et al.  Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome. , 2007, Atherosclerosis.

[9]  R. Muniyappa,et al.  Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. , 2008, American journal of physiology. Endocrinology and metabolism.

[10]  A. Jánosi,et al.  Rosuvastatin in older patients with systolic heart failure. , 2007, The New England journal of medicine.

[11]  S. Devaraj,et al.  Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome. , 2007, The American journal of cardiology.

[12]  T. Funahashi,et al.  Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. , 2007, Atherosclerosis.

[13]  C. White,et al.  Impact of statin dosing intensity on transaminase and creatine kinase. , 2007, The American journal of medicine.

[14]  Peter C Gøtzsche,et al.  Data extraction errors in meta-analyses that use standardized mean differences. , 2007, JAMA.

[15]  R. Kawamori,et al.  Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia. , 2007, Endocrine journal.

[16]  M. Hanefeld,et al.  Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. , 2007, Journal of the American College of Cardiology.

[17]  R. Haynes,et al.  Comparison of top-performing search strategies for detecting clinically sound treatment studies and systematic reviews in MEDLINE and EMBASE. , 2006, Journal of the Medical Library Association : JMLA.

[18]  K. Parhofer,et al.  Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome. , 2006, The American journal of cardiology.

[19]  M. Nakata,et al.  Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control , 2006, Diabetologia.

[20]  C Michael White,et al.  Statins and Cancer Risk: A Meta-analysis , 2007 .

[21]  S. Tonstad,et al.  A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. , 2005, European heart journal.

[22]  C. Tack,et al.  Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia , 2005, European journal of clinical investigation.

[23]  S. Khalifé,et al.  Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. , 2005, Metabolism: clinical and experimental.

[24]  Michael Schachter,et al.  Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update , 2005, Fundamental & clinical pharmacology.

[25]  Terrell Tannen.  Edward B Lewis , 2004, The Lancet.

[26]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[27]  Christopher P Cannon,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[28]  J. Hendriks,et al.  Nomogram to Diagnose Familial Combined Hyperlipidemia on the Basis of Results of a 5-Year Follow-Up Study , 2004, Circulation.

[29]  J. Levy,et al.  Use and abuse of HOMA modeling. , 2004, Diabetes care.

[30]  H. Koyama,et al.  Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment are useful indexes of insulin resistance in type 2 diabetic patients with wide range of fasting plasma glucose. , 2004, The Journal of clinical endocrinology and metabolism.

[31]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[32]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[33]  R. Casamitjana,et al.  Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C‐reactive protein in subjects with impaired fasting glucose , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[34]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[35]  G. Watts,et al.  Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. , 2003, Diabetes.

[36]  H. Altunbas,et al.  No Effect of Simvastatin Treatment on Insulin Sensitivity in Patients with Primary Hypercholesterolemia , 2003, Endocrine research.

[37]  Barry R. Davis,et al.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.

[38]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[39]  C. M. White.  A Review of the Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin , 2002, Journal of clinical pharmacology.

[40]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[41]  P. Serruys,et al.  Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[42]  P Hugh R Barrett,et al.  Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. , 2002, Clinical chemistry.

[43]  David Colquhoun,et al.  Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up , 2002, The Lancet.

[44]  R. Huupponen,et al.  Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. , 2002, JAMA.

[45]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[46]  A. Gotto,et al.  Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. , 2001, The American journal of cardiology.

[47]  P W Macfarlane,et al.  Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study , 2001, Circulation.

[48]  D A Follmann,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans , 2022 .

[49]  M. Nakata,et al.  Inhibition by simvastatin, but not pravastatin, of glucose‐induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L‐type Ca2+ channels in rat islet β‐cells , 1999, British journal of pharmacology.

[50]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[51]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[52]  R. Gregg,et al.  In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. , 1995, Toxicology and applied pharmacology.

[53]  J. Cutler,et al.  Variance imputation for overviews of clinical trials with continuous response. , 1992, Journal of clinical epidemiology.

[54]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.